Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions

05-Dec-2018 - Germany

Evotec AG announced a new integrated drug discovery alliance with LEO Pharma. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years.

The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology. Evotec’s integrated discovery scientists will work in a joint team with scientists from LEO Pharma. The alliance will receive further support with high-value drug development and discovery ADME-Tox services.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are delighted to partner with LEO Pharma on this exciting project, which leverages our industry-leading hit generation platform. Working together, we are convinced we will find innovative therapeutic approaches to dermatological conditions with a high unmet medical need.”

Dr Thorsten Thormann, Vice President, Research at LEO Pharma, said: “Innovation through partnerships plays a key role in LEO Pharma’s approach to developing new medicines. We are confident that our alliance with Evotec will further strengthen our research and help us expedite the discovery of novel small molecule therapeutics for skin diseases, for which there are large unmet medical needs, thus helping even more patients in the future.”

No financial details of this fee-for-service collaboration were disclosed.

https://www.bionity.com/en/news/1158675/evotec-and-leo-pharma-form-drug-discovery-alliance-targeting-dermatological-conditions.html